

K057707

JUL 15 2005

## **510(k) SUMMARY**

DENTSPLY International  
Susquehanna Commerce Center West  
221 West Philadelphia Street, Suite 60  
York, PA 17405-0872

CONTACT: Helen Lewis

DATE PREPARED: June 23, 2005

TRADE OR PROPRIETARY NAME: ECLIPSE® BONDING AGENT

CLASSIFICATION NAME: Denture relining, repairing, or rebasing resin, 872.3760

PREDICATE DEVICES: Trubyte® Denture Bond Denture Bonding Agent, K982007

### **DEVICE DESCRIPTION:**

The ECLIPSE® BONDING AGENT is a blend of reactive dimers and oligomers in a solvent vehicle. These reactive entities, once initiated, undergo polymerization across the interface between the teeth and the denture base resin to yield a strong and lasting bond. This formulation has been shown to be particularly effective in initiating and maintaining the bond between acrylic denture teeth and both pour and light-curable denture base resins.

The device is intended for use in the dental laboratory, by trained technicians, for the purpose of facilitating a bond between plastic denture teeth and cured denture base resins.

### **INTENDED USE:**

ECLIPSE® BONDING AGENT is indicated for use in enhancing the bond of acrylic teeth to acrylic removable denture bases.

### **TECHNOLOGICAL CHARACTERISTICS:**

The components of ECLIPSE® BONDING AGENT have been used in legally marketed devices or were found safe for dental use. We believe that the prior use of the initiator components in legally marketed devices, the data provided regarding the modifications to the marketed device, and the biocompatibility test results support the safety and effectiveness of ECLIPSE® BONDING AGENT for the intended use.



**DEPARTMENT OF HEALTH & HUMAN SERVICES**

Public Health Service

JUL 15 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Helen Lewis  
Director of Corporate Compliance and Regulatory Affairs  
DENTSPLY International  
Susquehanna Commerce Center West  
221 West Philadelphia Street, Suite 60  
York, Pennsylvania 17405-0872

Re: K051707  
Trade/Device Name: Eclipse® Bonding Agent  
Regulation Number: 21 CFR 872.3200  
Regulation Name: Resin Tooth Bonding Agent  
Regulatory Class: II  
Product Codes: KLE and EBI  
Dated: June 23, 2005  
Received: June 27, 2005

Dear Ms. Lewis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

  
Chiu S. Lin, PhD  
Director  
Division of Anesthesiology, General Hospital,  
Infection Control and Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## INDICATIONS FOR USE STATEMENT

510(K) Number (if known): K051707

Device Name: ECLIPSE® BONDING AGENT

### Indications for Use:

ECLIPSE® BONDING AGENT is indicated for use in enhancing the bond of acrylic teeth to acrylic removable denture bases.

Prescription Use X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE—CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Robert S. Betz DDS for Dr. Susan Runner  
(Division Sign-Off)  
Division of Anesthesiology, General Hospital,  
Infection Control, Dental Devices

510(k) Number: K051707